/

IPHA

Innate Pharma S.A.Closed

1.47−0.01 −0.68%USD

NasdaqGS · as of Oct 13, 16:00 ET · 15m delay

Open

1.47

Prev close

1.48

Day range

1.451.48

52-week range

1.172.71

Volume

5.61K0.03×

Mkt cap

164.20M

P/E ttm

—

Fwd P/E

-3.12

EPS ttm

-0.5900

Div yield

0.00%

Earnings

Nov 5, 2026

From 52w high

−45.76%

Price Chart

Yahoo Finance · delayed

IPHAOct 13, 2026O 1.47H 1.48L 1.45C 1.47−0.01 (−0.68%)Vol 5.60K

SMA 501.92
SMA 2001.73

1Y change −27.59% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

IPHA Innate Pharma S.A. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −7.55%
1 month: −21.39%
3 months: −17.88%
6 months: −9.82%
Year to date: −16.00%
1 year: −25.76%

Valuation & ownership

Market cap: 164.20M
Enterprise value: 147.05M
P/E (ttm): —
Forward P/E: -3.12
PEG ratio: —
Price / book: —
Price / sales (ttm): 16.74
EV / EBITDA: -3.13
EPS (ttm): -0.5900
EPS (forward): -0.4715
Beta (5y monthly): 1.19
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 111.70M
Float: 70.45M
Short % of float: 0.08%
Short ratio (days): 1.92
Held by insiders: 1.40%
Held by institutions: 0.35%
Avg volume (3m): 160.28K
50-day average: 1.93
200-day average: 1.73
52-week change: −25.76%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 34.0
vs 50-day SMA: −23.50%
vs 200-day SMA: −15.08%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 8.19%
Realised vol (20d, ann.): 66.6%
From 52-week high: −45.76%
From 52-week low: +25.64%

ANR

Analyst Consensus

3 analysts

Consensus

—

Mean target

6.67

+353.51% implied

Low 4.00Median 7.00High 9.00

Recommendation trend

Now3 / 0 / 0
1m ago3 / 0 / 0

Buy / hold / sell counts

Recent actionsAll (UPDN) →

DES

About Innate Pharma S.A.

Yahoo Finance profile

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.

Sector: Healthcare
Industry: Biotechnology
Employees: 120
Headquarters: Marseille, France
Website: innate-pharma.com
Officers: Mr. Jonathan E. Dickinson B.Sc., M.B.A. CEO & Director
Mr. Yannis Morel Ph.D.

SEAS

Seasonality · IPHA

2019–2026 · monthly returns

Strongest month Dec +10.05%Weakest month Jun −8.45%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	4.6	-6.3	-25.4	12.5	27.1	0.5	-4.9	24.0	-24.9	-9.8			−16.0%
2025	-0.5	15.8	-16.0	25.3	-1.8	-17.1	16.3	2.4	-10.6	2.1	-1.0	-10.3	−4.9%
2024	-4.3	-2.2	9.9	-19.8	18.6	-29.2	10.6	7.0	-0.2	-17.4	-18.6	19.5	−34.3%
2023	-7.6	-14.4	-3.4	3.5	-0.3	4.6	-4.4	-1.0	-13.1	-2.4	-2.8	16.7	−24.9%
2022	-16.9	-10.0	-1.5	-14.6	-7.3	1.5	18.5	-16.2	-25.4	7.5	0.0	73.5	−18.2%
2021	0.0	12.2	-6.1	-1.6	-7.8	-15.9	0.9	9.6	69.5	-6.0	-14.5	-8.1	+11.5%
2020	9.0	-10.8	6.7	13.8	-14.5	5.4	-11.3	2.2	-38.2	14.3	21.6	-23.4	−36.5%
2019											5.6	2.5	+8.2%

IPHA

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

IPHA

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Innate Pharma S.A.

Seasonality · IPHA

Insider Activity · IPHA

Congress Trades · IPHA

Investors Holding IPHA

Investors Holding IPHA

Congress Trades · IPHA

Insider Activity · IPHA

Seasonality · IPHA

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Innate Pharma S.A.

Financial Snapshot

Earnings & Dividends

News